Oncternal Therapeutics In... (ONCT)
NASDAQ: ONCT
· Real-Time Price · USD
0.53
-0.16 (-23.63%)
At close: Dec 02, 2024, 10:00 PM
Oncternal Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -34.58M | -35.97M | -36.38M | -39.48M | -41.72M | -42.98M | -45.75M | -44.17M | -40.84M | -39.35M | -35.29M | -31.33M | -25.82M | -20.58M | -18.43M |
Depreciation & Amortization | 329K | 404K | 441K | 441K | 37K | -3K | 25K | 69K | 188K | 196K | 173K | 169K | 125K | 82K | 40K |
Stock-Based Compensation | 6.81M | 6.68M | 6.97M | 7.5M | 7.08M | 7.34M | 7.34M | 7.43M | 7.34M | 6.86M | 7.01M | 5.88M | 4.57M | 3.49M | 2M |
Other Working Capital | 1.8M | 5.51M | 2.6M | 3.04M | 1.36M | -4.43M | 123K | -1.03M | -715K | 2.05M | -1.61M | -2.12M | -4.27M | -5.24M | -3.54M |
Other Non-Cash Items | 2.25M | 903K | -284K | -1.46M | -1.08M | -764K | -269K | 179K | 188K | 196K | 173K | 169K | -137K | -142K | -147K |
Deferred Income Tax | 112K | 37K | n/a | n/a | -112K | -72K | -100K | -100K | -100K | -65K | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 869K | 5.19M | 2.1M | 1.27M | 1.04M | -4.72M | -308K | -69K | -1M | 3.56M | -1.11M | -1.3M | -2.5M | -5.59M | -2.86M |
Operating Cash Flow | -26.63M | -25.19M | -28.63M | -32.16M | -34.75M | -41.2M | -39.07M | -36.7M | -34.32M | -28.73M | -29.21M | -26.59M | -23.88M | -22.83M | -19.44M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -28.13M | -43.47M | -52.33M | -64.35M | -79.04M | -63.69M | -48.55M | -26.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 53M | 59.35M | 76.25M | 65M | 55M | 35M | 6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 11.22M | 15.88M | 23.92M | 16.7M | -7.99M | -12.65M | -26.5M | -26.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 24.87M | 15.88M | 23.92M | 651K | -24.04M | -28.69M | -42.55M | -26.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | -88K | -137K | -138K | -156K | -155K | -109K | -108K | -3K | -3K | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | 3.7M | 3.7M | 3.7M | 3.7M | 98K | 158K | 617K | 616K | 519K | 5.28M |
Financial Cash Flow | -88K | -137K | -138K | 1.07M | 3.08M | 6.83M | 10.7M | 9.58M | 7.57M | 3.97M | 158K | 617K | 100M | 109.88M | 114.64M |
Net Cash Flow | -1.85M | -9.45M | -4.85M | -30.45M | -55.7M | -63.07M | -70.92M | -53.62M | -26.75M | -24.76M | -29.05M | -25.97M | 76.12M | 87.05M | 95.19M |
Free Cash Flow | -26.63M | -25.19M | -28.63M | -32.16M | -34.75M | -41.2M | -39.07M | -36.7M | -34.32M | -28.73M | -29.21M | -26.59M | -23.88M | -22.83M | -19.44M |